Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06283511
Other study ID # IJB-RESTART
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date February 2024
Est. completion date December 2026

Study information

Verified date January 2024
Source Jules Bordet Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

The RESTART survivorship programme has been implemented in the care pathway for patients with localised breast cancer since 2022. In this project, investigators are going to evaluate the satisfaction of patients taking part in the RESTART programme, as well as measuring changes in quality of life and health literacy after participation in the RESTART programme.


Description:

Prospective longitudinal, single-centre, non-randomised study for patients who have completed acute treatment (surgery, radiotherapy, chemotherapy) for localised breast cancer within the last 3 months. In this project, investigtors are going to evaluate the satisfaction of patients taking part in the RESTART programme, as well as measuring changes in quality of life and health literacy after participation in the RESTART programme. The primary objective is to assess satisfaction with participation in the Restart programme and its various components. Evaluation criteria associated with the primary objective: Measurement of overall satisfaction and of the various components of the RESTART programme (Likert scale and open questions) - Evaluation criteria associated with the secondary objective: To measure before starting the RESTART programme and 1 and 12 months after the end of the programme: - Patients' Quality of Life (QoL) (using the EORTC30 and BR23 questionnaires for breast cancer) - Health literacy (via the HLQ questionnaire) - Professional status - Patients' physical activity level via the Global Physical Activity Questionnaire (GPAQ) - Psychological distress, anxiety and depressive symptoms via the Generalized Anxiety Disorder - 7 (GAD-7) and Patient Health Questionnaire-9 (PHQ-9) questionnaires - Fatigue (via the NRS) - Patient sleep quality using the Pittsburgh Sleep Quality Index (PSQI) To measure the rate of participation in the programme via the proportion of patients who participated in relation to the number of patients operated on for breast cancer located in Bordet during the same period.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 200
Est. completion date December 2026
Est. primary completion date August 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 99 Years
Eligibility Inclusion Criteria: 1. Age >= 18 at the time of signing the ICF 2. Minimum understanding of French 3. Signed study informed consent form obtained prior to any study-related procedure. 4. Participation in the RESTART programme 5. Patient with curative breast cancer (AJCC stage I-II-III) Exclusion Criteria: -

Study Design


Related Conditions & MeSH terms


Intervention

Other:
educational workshops
patient will be proposed to assist to educational workshops + the possibility to assist to a physical rehabilitation programme

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Jules Bordet Institute

Outcome

Type Measure Description Time frame Safety issue
Primary Assessment of satisfaction with participation in the Restart programme and its various components via Likert scale and open questions. To assess the global satisfaction with participation in the Restart programme and its various components via the Likert Scale. 1 month after end of programme and 12 months after end of the programme
Secondary assessment of quality of life To measure changes in quality of life via EORTC30 questionnaire baseline - 1 month after end of programme - 12 months after end of programme
Secondary assessemnt of health literacy via HLQ questionnaire to mesure changes in health literacy via HLQ questionnaire baseline - 1 month after end of programme - 12 months after end of programme
Secondary assessment of professional status to assess the number of patients who return to work via open question baseline - 1 month after end of programme- 12 months after end of programme
Secondary assessment of level of physical activity to measure the changes in level of physical activity via the Global Physical Activity Questionnaire (GPAQ) baseline - 1 month after end of programme- 12 months after end of programme
Secondary assessment of emotionnal distress to measure the changes in emotional distress via questionnaire "generalized Anxiety Disorder" (GAD-7) baseline - 1 month after end of programme- 12 months after end of programme
Secondary assessment of the intensity of residual fatigue to measure the intensity of residual fatigue via NRS (0= no fatigue and 10 = worst fatigue) baseline - 1 month after end of programme- 12 months after end of programme
Secondary assessment of sleep quality changes in sleep quality via Pittsburgh sleep Quality index (PSQI) before and after participation in the RESTART programme. baseline - 1 month after end of programme - 12 months after end of programme
Secondary Measuring the rate of participation in the programme Measure the participation rate in the program via the proportion of patients who participated compared to the number of patients operated on for breast cancer located in Bordet during the same period. baseline - 1 month after end of programme - 12 months after end of programme
Secondary assessment of quality of life To measure changes in quality of life via BR 23 questionnaire baseline - 1 month after end of programme - 12 months after end of programme
Secondary assessment of emotionnal distress to measure the changes in emotional distress via questionnaire "Patient Health Questionnaire-9" (PHQ-9) baseline - 1 month after end of programme- 12 months after end of programme
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03595592 - Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer Phase 3
Recruiting NCT05383196 - Onvansertib + Paclitaxel In TNBC Phase 1/Phase 2
Recruiting NCT06158217 - Effect of Ultrasound Combined With Microbubbles on Blood Perfusion in Invasive Breast Cancer
Active, not recruiting NCT04448886 - Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC Phase 2
Completed NCT02773784 - Comparison of CNB and Surgical Specimens for ER, PgR, HER2 Status and Ki67 Index in Invasive Breast Cancer.
Recruiting NCT01509781 - Suction Drain Versus the Use of Adaptive Skin Sutures After Mastectomy ± Axillary Lymphadenectomy; a Prospective Randomised Study Phase 3
Completed NCT04478669 - Digital Breast Tomosynthesis (DBT) to Improve Assessment of Resection Margins in Invasive Breast Cancer
Recruiting NCT04553770 - Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer Phase 2
Recruiting NCT04677816 - Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients Phase 2
Terminated NCT01934335 - Effect of Vandetanib on Cellular Markers in Invasive Breast Cancer Phase 2
Completed NCT00507611 - Axillary Lymph Node Status After Completion of Preoperative Neoadjuvant Systemic Chemotherapy in Patients N/A
Completed NCT00581750 - Molecular Genetic Basis of Invasive Breast Cancer Risk Associated With Lobular Carcinoma in Situ
Completed NCT03304171 - Overall Diet Quality and Breast Cancer Risk N/A
Completed NCT03709186 - Radiomic Markers for Breast Cancer Metastasis and Treatment Response Using MRI
Terminated NCT03361800 - Window of Opportunity Trial of Entinostat in Patients With Newly Diagnosed Stage I-IIIC,TNBC Early Phase 1
Recruiting NCT04648904 - Study of a Shortened Radiation Therapy Schedule in People With Breast Cancer Early Phase 1
Recruiting NCT06328465 - fREEDOM: REsonance for Early Detection Of Breast Cancer Metastases N/A
Active, not recruiting NCT03109522 - Axillary Reverse Mapping (ARM) Technique N/A
Recruiting NCT03987555 - Paclitaxel Therapeutic Drug Monitoring in Cancer Patients
Recruiting NCT03497702 - Neo-adjuvant Chemotherapy With Letrozole in Patients With Estrogen Receptor Positive/HER-2 Negative Breast Cancer Phase 2